Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma

Multiple myeloma (MM) remains an incurable disease regardless of recent advances in the field. Therefore, a substantial unmet need exists to treat patients with relapsed/refractory myeloma. The use of novel agents such as daratumumab, elotuzumab, carfilzomib, or pomalidomide, among others, usually c...

Full description

Bibliographic Details
Main Authors: Estefanía García-Guerrero, Belén Sierro-Martínez, Jose Antonio Pérez-Simón
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Immunology
Subjects:
CAR T-cell
myeloma
toxicities
antigen escape
soluble protein
allogeneic CAR T-cell
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01128/full

Similar Items

Similar Items